Metastatic Breast Cancer - Pipeline Review, Q1 2011

Transcription

1 Brochure More information from Metastatic Breast Cancer - Pipeline Review, Q Description: Metastatic Breast Cancer - Pipeline Review, Q Summary Global Markets Direct s, 'Metastatic Breast Cancer - Pipeline Review, Q1 2011', provides an overview of the Metastatic Breast Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer. 'Metastatic Breast Cancer - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Scope - A snapshot of the global therapeutic scenario for Metastatic Breast Cancer. - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Breast Cancer pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Metastatic Breast Cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Contents: List of Tables List of Figures Introduction Global Markets Direct Report Coverage Metastatic Breast Cancer Overview Therapeutics Development An Overview of Pipeline Products for Metastatic Breast Cancer Metastatic Breast Cancer Therapeutics under Development by Companies Metastatic Breast Cancer Therapeutics under Investigation by Universities/Institutes Late Stage Products

2 Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Companies Involved in Metastatic Breast Cancer Therapeutics Development Bristol-Myers Squibb Company Abraxis BioScience, Inc. Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. Abbott Laboratories Biogen Idec Inc. Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Merck & Co., Inc. Infinity Pharmaceuticals, Inc. Plexxikon Inc. Celltrion, Inc. Novartis AG Astellas Pharma Inc. Eisai Co., Ltd. Pfizer Inc. Cell Therapeutics, Inc. Santaris Pharma A/S Bayer AG Incyte Corporation Geron Corporation Merck KGaA EntreMed, Inc. Peregrine Pharmaceuticals, Inc. Allos Therapeutics, Inc Legacy Health System iomedico AG Array BioPharma Inc. InterMed Discovery GmbH Quantum Immunologics, Inc. Fresenius Biotech GmbH PTC Therapeutics, Inc. Marillion Pharmaceuticals, Inc. Immutep S.A. Syndax Pharmaceuticals, Inc. Sopherion Therapeutics, LLC AVEO Pharmaceuticals, Inc. Providence Health & Services Kyowa Hakko Kirin Pharma, Inc. BN ImmunoTherapeutics, Inc. Regulon Inc. Hoosier Oncology Group, Inc. Accelerated Community Oncology Research Network, Inc. Pharmatech Oncology, Inc Universities/Institutes Involved in Metastatic Breast Cancer Therapeutics Development Metastatic Breast Cancer Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type

3 Late Stage Drug Profiles Companies Arzoxifene - Drug Profile Avastin + Taxane - Drug Profile BSI Drug Profile DOXIL/CAELYX + Docataxel - Drug Profile Everolimus + Trastuzumab + Vinorelbine - Drug Profile Fluorouracil + Doxorubicin + Cyclophosphamide + Taxol - Drug Profile Gemcitabine + Docetaxel - Drug Profile GW Letrozole - Drug Profile Herceptin + Arimidex - Drug Profile Herceptin + Paclitaxel - Drug Profile IMC-1121B + Docetaxel - Drug Profile Lapatinib + Trastuzumab + Anastrozole - Drug Profile Lapatinib + Trastuzumab + Exemestane - Drug Profile Lapatinib + Trastuzumab + Letrozole - Drug Profile Myocet + Taxol + Herceptin - Drug Profile Neratinib + Paclitaxel - Drug Profile

4 Paclitaxel + GW Drug Profile Paclitaxel + Trastuzumab + GW Drug Profile Pertuzumab + Trastuzumab + Docetaxel - Drug Profile RAD001 + Trastuzumab + Paclitaxel - Drug Profile Sarasar - Drug Profile Trastuzumab-DM1 + Pertuzumab - Drug Profile Votrient + Tykerb - Drug Profile Late Stage Drug Profiles Universities/Institutes 5-Fluorouracil + Leucovorin + Adriamycin + Cytoxan + Granulocyte-Macrophage Colony-Stimulating Factor - Drug Profile Adiramycin + Cyclophosphamide + Docetaxel - Drug Profile Anastrozole + Fulvestrant - Drug Profile Avastin + Docetaxel - Drug Profile Bevacizumab + Capecitabine - Drug Profile bevacizumab + capecitabine + cyclophosphamide + paclitaxel - Drug Profile Bevacizumab + Cyclophosphamide + Methotrexate - Drug Profile Bevacizumab + Ixabepilone - Drug Profile

5 Bevacizumab + Letrozole/Fulvestrant - Drug Profile Bevacizumab + Paclitaxel - Drug Profile Bevacizumab + Paclitaxel for Metastatic Breast Cancer (Central European Cooperative Oncology Group) - Drug Profile Capecitabine - Drug Profile Capecitabine - Drug Profile Capecitabine for Metastatic Breast Cancer (Hospital San Carlos, Madrid) - Drug Profile Carboplatin + Paclitaxel + Trastuzumab + Bevacizumab - Drug Profile cyclophosphamide + epirubicin hydrochloride - Drug Profile cyclophosphamide + doxorubicin hydrochloride + prednisolone + vincristine sulfate - Drug Profile Docetaxel + Epirubicin + Cyclophosphamide + 5-fluoruracil + Granulocyte-colony stimulating growth factor - Drug Profile Docetaxel + Epirubicin + Cyclophosphamide + 5-fluoruracil + Trastuzumab + Granulocyte-colony stimulating growth factor - Drug Profile Docetaxel + Pertuzumab + Trastuzumab - Drug Profile Docetaxel/Paclitaxel - Drug Profile Doxorubicin + Docetaxel - Drug Profile Doxorubicin + Paclitaxel - Drug Profile

6 Epirubicin + Cyclophosphamide - Drug Profile Epirubicin + Cyclophosphamide - Drug Profile Epirubicin + Docetaxel - Drug Profile Epirubicin + Paclitaxel - Drug Profile Epirubicin Hydrochloride + Paclitaxel - Drug Profile Eribulin Mesylate - Drug Profile Exemestane for Metastatic Breast Cancer (Institute of Cancer Research) - Drug Profile Faslodex + Arimidex - Drug Profile Faslodex for Metastatic Breast Cancer (Institute of Cancer Research) - Drug Profile FEC Chemotherapy + DG Chemotherapy - Drug Profile FEC Chemotherapy + Docetaxel - Drug Profile Filgrastim + Cisplatin + Cyclophosphamide + Etoposide + Stem Cell Transplantation - Drug Profile Filgrastim + Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Thiotepa - Drug Profile Fulvestrant + Exemestane + Anastrozole + Letrozole - Drug Profile Fulvestrant + Lapatinib ditosylate + Exemestane + Anastrozole + Letrozole - Drug Profile Fulvestrant + Lapatinib ditosylate. - Drug Profile

7 Fulvestrant. - Drug Profile G-CSF + Trastuzumab + Vinorelbine - Drug Profile Gemcitabine + Vinorelbine - Drug Profile Ixabepilone + Bevacizumab - Drug Profile Letrozole - Drug Profile Marimastat - Drug Profile Paclitaxel + Bevacizumab - Drug Profile Paclitaxel + Epirubicin + Cyclophosphamide + 5-fluoruracil + Granulocyte-colony stimulating growth factor - Drug Profile Paclitaxel + Trastuzumab - Drug Profile Pegylated Liposomal Doxorubicin - Drug Profile Prophylactic Cranial Irradiation + Herceptin - Drug Profile Taxol - Drug Profile Trastuzumab - Drug Profile trastuzumab - Drug Profile trastuzumab + paclitaxel - Drug Profile

8 Trastuzumab + Vinorelbine Ditartrate - Drug Profile TS-1 - Drug Profile vinorelbine + trastuzumab - Drug Profile Zoledronic Acid - Drug Profile Discontinued Products Metastatic Breast Cancer - Featured News Dec 12, 2010: Nektar Reports Positive Phase II Study Results Of NKTR-102 In Metastatic Breast Cancer Dec 10, 2010: AVEO Announces Preliminary Results From Phase Ib Study With Tivozanib In Combination With Paclitaxel For Metastatic Breast Cancer Dec 10, 2010: ImmunoGen Reports Phase Ib/II Clinical Data For T-DM1 Used In Combination With Pertuzumab For Treatment Of Metastatic Breast Cancer Dec 09, 2010: Nektar To Present Phase II Clinical Data On NKTR-102 At Annual CTRC-AACR San Antonio Breast Cancer Symposium Dec 08, 2010: Boehringer Ingelheim Begins Phase III Trial With Afatinib In Advanced Breast Cancer Dec 02, 2010: AVEO To Present New Clinical Data Of Tivozanib At Annual San Antonio Breast Cancer Symposium Nov 08, 2010: Genta Initiates Phase IIb Trial With Tesetaxel As First-Line Chemotherapy For Women With Metastatic Breast Cancer Oct 08, 2010: ImmunoGen Announces Positive Interim Clinical Results Of Trastuzumab-DM1 For Treatment Of Metastatic Breast Cancer Oct 01, 2010: Array BioPharma Announces Positive Interim Phase I Results For ARRY-380 In Breast Cancer Patients Aug 30, 2010: Eisai Receives Extension Of FDA Review Of Drug Application For Investigational Agent Eribulin Mesylate Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products Under Development for Metastatic Breast Cancer, 2011 Products under Development for Metastatic Breast Cancer Comparative Analysis, 2011 Comparative Analysis by Late Stage Development, 2011 Comparative Analysis by Mid Clinical Stage Development, 2011 Comparative Analysis by Early Clinical Stage Development, 2011 Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011 Bristol-Myers Squibb Company, 2011 Abraxis BioScience, Inc., 2011 Johnson & Johnson, 2011 Boehringer Ingelheim GmbH, 2011 F. Hoffmann-La Roche Ltd., 2011 Abbott Laboratories, 2011 Biogen Idec Inc., 2011 Amgen Inc., 2011 Sanofi-Aventis, 2011

9 Adherex Technologies Inc., 2011 AstraZeneca PLC, 2011 Eli Lilly and Company, 2011 GlaxoSmithKline plc, 2011 Merck & Co., Inc., 2011 Infinity Pharmaceuticals, Inc., 2011 Plexxikon Inc., 2011 Celltrion, Inc., 2011 Novartis AG, 2011 Astellas Pharma Inc., 2011 Eisai Co., Ltd., 2011 Pfizer Inc., 2011 Cell Therapeutics, Inc., 2011 Santaris Pharma A/S, 2011 Bayer AG, 2011 Incyte Corporation, 2011 Geron Corporation, 2011 Merck KGaA, 2011 EntreMed, Inc., 2011 Peregrine Pharmaceuticals, Inc., 2011 Allos Therapeutics, Inc, 2011 Legacy Health System, 2011 iomedico AG, 2011 Array BioPharma Inc., 2011 InterMed Discovery GmbH, 2011 Quantum Immunologics, Inc., 2011 Fresenius Biotech GmbH, 2011 PTC Therapeutics, Inc., 2011 Marillion Pharmaceuticals, Inc., 2011 Immutep S.A., 2011 Syndax Pharmaceuticals, Inc., 2011 Sopherion Therapeutics, LLC, 2011 AVEO Pharmaceuticals, Inc., 2011 Providence Health & Services, 2011 Kyowa Hakko Kirin Pharma, Inc., 2011 BN ImmunoTherapeutics, Inc., 2011 Regulon Inc., 2011 Hoosier Oncology Group, Inc., 2011 Accelerated Community Oncology Research Network, Inc., 2011 Pharmatech Oncology, Inc, 2011 Assessment by Monotherapy Products, 2011 Assessment by Combination Products Assessment by Stage and Route of Administration, 2011 Assessment by Molecule Type, 2011 Discontinued Products List of Figures Number of Products under Development for Metastatic Breast Cancer, 2011 Products under Development for Metastatic Breast Cancer Comparative Analysis, 2011 Products under Development by Companies, 2011 Products under Investigation by Universities/Institutes, 2011 Late Stage Products, 2011 Mid Clinical Stage Products, 2011 Early Clinical Stage Products, 2011 Discovery and Pre-Clinical Stage Products, 2011 Assessment by Monotherapy Products, 2011 Assessment by Combination Products, 2011 Assessment by Route of Administration, 2011 Assessment by Stage and Route of Administration, 2011 Assessment by Molecule Type, 2011 Assessment by Stage and Molecule Type, 2011

10 Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

11 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Metastatic Breast Cancer - Pipeline Review, Q Web Address: Office Code: Product Formats Please select the product formats and quantity you require: SC Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 500 USD 1000 USD 1500 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

12 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World